Bariatric Surgery Tied to Lower Risk of MACE, Death in Obesity, Sleep Apnea
By Elana Gotkine HealthDay Reporter
FRIDAY, June 28, 2024 -- Metabolic surgery is associated with significantly lower risk of major adverse cardiovascular events (MACE) compared with nonsurgical management among patients with moderate-to-severe obstructive sleep apnea (OSA) and obesity, according to a study published online June 21 in the Journal of the American College of Cardiology.
Ali Aminian, M.D., from the Bariatric and Metabolic Institute at the Cleveland Clinic, and colleagues examined the long-term relationship between metabolic surgery and incident MACE in patients with OSA and obesity (body mass index, 35 to 70 kg/m2). Patients who underwent metabolic surgery were matched with a nonsurgical control group using overlap weighting methods. Data were included for 970 patients in the metabolic surgery group and 12,687 in the nonsurgical group, with median follow-up of 5.3 years.
The researchers found that the mean between-group difference in body weight at 10 years was 26.6 kg (19.3 percent). The 10-year cumulative incidence of MACE was 27.0 and 35.6 percent in the metabolic surgery and nonsurgical groups, respectively (adjusted hazard ratio, 0.58). The 10-year cumulative incidence of all-cause mortality was 9.1 and 12.5 percent in the metabolic surgery and nonsurgical groups, respectively (adjusted hazard ratio, 0.63).
"In select patients, bariatric surgery is a lifesaving treatment," Aminian said in a statement. "The MOSAIC study suggests the presence of a dose-dependent response between the amount of weight loss and cardiovascular benefits in patients with obstructive sleep apnea; the greater the weight loss, the lower the risk of heart complications."
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death
WEDNESDAY, May 28, 2025 -- For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related...
Post-Kidney Transplant Adverse Outcomes Increased With BMI-BSA Obesity
TUESDAY, May 27, 2025 -- Combined body mass index (BMI)-body surface area (BSA) obesity is associated with an increased risk for post-kidney transplant (KT) adverse outcomes...
Semaglutide Plus Intensive Behavioral Therapy Most Beneficial for Weight Loss
FRIDAY, May 23, 2025 -- Weight loss treatment combining personalized semaglutide with intensive behavioral therapy (IBT) yields weight loss similar to that reported in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.